New insights into eicosanoid biosynthetic pathways: Implications for arthritis

Expert Review of Clinical Immunology

Volumn 2, Issue 2, 2006, Pages 277-291

  Kojima, Fumiaki ^a   Kapoor, Mohit ^a   Kawai, Shinichi ^b   Crofford, Leslie J ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b TOHO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; ARACHIDONIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYCLOOXYGENASE 3; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ETODOLAC; HYDROXYICOSATETRAENOIC ACID; IBUPROFEN; ICOSANOID; INDOMETACIN; LEUKOTRIENE B4; LEUKOTRIENE DERIVATIVE; LEUKOTRIENE RECEPTOR; LIPOXIN; LIPOXIN RECEPTOR; MELOXICAM; MKK 886; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; ROFECOXIB; THROMBOXANE; UNINDEXED DRUG;

ARACHIDONIC ACID METABOLISM; ARTHRITIS; CARDIOVASCULAR DISEASE; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY DYSFUNCTION; LIPOGENESIS; NONHUMAN; OSTEOARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

EID: 33748479488     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.2.2.277     Document Type: Review

References (168)

1. Crofford LJ. COX-2: where are we in 2003? - Specific cyclooxygenase-2 inhibitors and aspirin-exacerbated respiratory disease. Arthritis Res. Ther. 5(1), 25-27 (2003).
2. Crofford LJ. Specific cyclooxygenase-2 inhibitors: what have we learned since they came into widespread clinical use? Curr. Opin Rheumatol. 14(3), 225-230 (2002).
3. Crofford LJ. Is there a place for non-selective NSAIDs in the treatment of arthritis? Joint Bone Spine. 69(1), 4-7 (2002).
4. Simon LS, Smolen JS, Abramson SB et al. Controversies in COX-2 selective inhibition. J. Rheumatol. 29(7), 1501-1510 (2002).
5. Watanabe T, Higuchi K, Taira K et al. Rebamipide reduces delay in gastric ulcer healing in cyclooxygenase-2-deficient mice. Dig. Dis. Sci. 50, 63-69 (2005).
6. Sampey AV, Monrad S, Crofford LJ. Microsomal prostaglandin E synthase-1: the inducible synthase for prostaglandin E2. Arthritis Res. Ther. 7(3), 114-117 (2005).
7. Kojima F, Kato S, Kawai S. Prostaglandin E synthase in the pathophysiology of arthritis. Fundam. Clin. Pharmacol. 19(3), 255-261 (2005).
8. McInnes IB. Leukotrienes, mast cells, and T cells. Arthritis Res. Ther. 5(6), 288-289 (2003).
9. Zwerina J, Redlich K, Schett G, Smolen JS. Pathogenesis of rheumatoid arthritis: targeting cytokines. Ann. NY Acad. Sci. 1051, 716-729 (2005).
10. Sweeney SE, Firestein GS. Rheumatoid arthritis: regulation of synovial inflammation. Int. J. Biochem. Cell Biol. 36, 372-378 (2004).
11. Hitchon CA, El-Gabalawy HS. Oxidation in rheumatoid arthritis. Arthritis Res. Ther. 6(6), 265-278 (2004).
12. Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: role in arthritis. Front. Biosci. 11, 529-543 (2006).
13. Ben-Av P, Crofford LJ, Wilder RL, Hla T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett. 372(1), 83-87 (1995).
14. Pap T, Distler O. Linking angiogenesis to bone destruction in arthritis. Arthritis Rheum. 52(5), 1346-1348 (2005).
15. Crofford LJ. Prostaglandin biology. Gastroenterol. Clin. North Am. 30(4), 863-876 (2001).
16. Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc. Natl Acad. Sci. USA 88(7), 2692-2696 (1991).
17. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J. Biol. Chem. 266(20), 12866-12872 (1991).
18. Vane JR, Botting RM. Mechanism of action of anti-inflammatory drugs. Scand. J. Rheumatol. 102(Suppl.), 9-21 (1996).
19. Jones DA, Carlton DP, McIntyre TM, Zimmerman GA, Prescott SM. Molecular cloning of human prostaglandin endoperoxide synthase Type II and demonstration of expression in response to cytokines. J. Biol. Chem. 268(12), 9049-9054 (1993).
20. Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J. Am. Coll. Nutr. 21, 495-505 (2002).
21. Chandrasekharan NV, Dai H, Roos KL et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc. Natl Acad. Sci. USA 99(21), 13926-13931 (2002).
22. Dinchuk JE, Liu RQ, Trzaskos JM. COX-3: in the wrong frame in mind. Immunol. Lett. 86(1), 121 (2003).
23. Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. J. Rheumatol. 49, 15-19 (1997).
24. Crofford LJ. COX-2 in synovial tissues. Osteoarthritis Cartilage. 7(4), 406-408 (1999).
25. Siegle I, Klein T, Backman JT, Saal JG, Nusing RM, Fritz P. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human synovial tissue: differential elevation of cyclooxygenase-2 in inflammatory joint diseases. Arthritis Rheum. 41(1), 122-129 (1998).
26. Kang RY, Freire-Moar J, Sigal E, Chu CQ. Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis. Br. J. Rheumatol. 35(8), 711-718 (1996).
27. Crofford LJ, Wilder RL, Ristimaki AP et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1β, phorbol ester, and corticosteroids. J. Clin. Invest. 93(3), 1095-1101 (1994).
28. Hulkower KI, Wertheimer SJ, Levin W et al. Interleukin-1 β induces cytosolic phospholipase A2 and prostaglandin H synthase in rheumatoid synovial fibroblasts. Evidence for their roles in the production of prostaglandin E2. Arthritis Rheum. 37(5), 653-661 (1994).
29. Angel J, Berenbaum F, Le Denmat C, Nevalainen T, Masliah J, Fournier C. Interleukin-1-induced prostaglandin E2 biosynthesis in human synovial cells involves the activation of cytosolic phospholipase A2 and cyclooxygenase-2. Eur. J. Biochem. 226(1), 125-131 (1994).
30. Sano H, Hla T, Maier JA et al. In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J. Clin. Invest. 89(1), 97-108 (1992).
31. Lyons-Giordano B, Pratta MA, Galbraith W, Davis GL, Arner EC. Interleukin-1 differentially modulates chondrocyte expression of cyclooxygenase-2 and phospholipase A2. Exp. Cell Res. 206(1), 58-62 (1993).
32. Geng Y, Blanco FJ, Cornelisson M, Lotz M. Regulation of cyclooxygenase-2 expression in normal human articular chondrocytes. J. Immunol. 155(2), 796-801 (1995).
33. Chan CC, Boyce S, Brideau C et al. Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally-active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J. Pharmacol. Exp. Ther. 290(2), 551-560 (1999).
34. Ochi T, Goto T. Differential effect of FR122047, a selective cyclo-oxygenase-1 inhibitor, in rat chronic models of arthritis. Br. J. Pharmacol. 135(3), 782-788 (2002).
35. Ochi T, Ohkubo Y, Mutoh S. Role of cyclooxygenase-2, but not cyclooxygenase-1, on Type II collagen-induced arthritis in DBA/1J mice. Biochem. Pharmacol. 66(6), 1055-1060 (2003).
36. Myers LK, Kang AH, Postlethwaite AE et al. The genetic ablation of cyclooxygenase-2 prevents the development of autoimmune arthritis. Arthritis Rheum. 43(12), 2687-2693 (2000).
37. Liagre B, Vergne-Salle P, Corbiere C, Charissoux JL, Beneytout JL. Diosgenin, a plant steroid, induces apoptosis in human rheumatoid arthritis synoviocytes with cyclooxygenase-2 overexpression. Arthritis Res. Ther. 6(4), 373-383 (2004).
38. Urade Y, Watanabe K, Hayaishi O. Prostaglandin D, E, and F synthases. J. Lipid Mediat. Cell Signal. 12(2-3), 257-273 (1995).
39. 2. J. Biol. Chem. 276(37), 34918-34927 (2001).
40. Tanioka T, Nakatani Y, Semmyo N, Murakami M, Kudo I. Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J. Biol. Chem. 275(42), 32775-32782 (2000).
41. Jakobsson PJ, Thoren S, Morgenstern R, Samuelsson B. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc. Natl Acad. Sci. USA 96(13), 7220-7225 (1999).
42. Murakami M, Naraba H, Tanioka T et al. Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J. Biol. Chem. 275(42), 32783-32792 (2000).
43. Murakami M, Nakashima K, Kamei D et al. Cellular prostaglandin E2 production by membrane-bound prostaglandin E synthase-2 via both cyclooxygenases-1 and -2. J. Biol. Chem. 278(39), 37937-37947 (2003).
44. Nagata A, Suzuki Y, Igarashi M et al. Human brain prostaglandin D synthase has been evolutionarily differentiated from lipophilic-ligand carrier proteins. Proc. Natl Acad. Sci. USA 88, 4020-4024 (1991).
45. Kanaoka Y, Ago H, Inagaki E et al. Cloning and crystal structure of hematopoietic prostaglandin D synthase. Cell 90(6), 1085-1095 (1997).
46. Urade Y, Eguchi N. Lipocalin-type and hematopoietic prostaglandin D synthases as a novel example of functional convergence. Prostaglandins Other Lipid Mediat. 68, 375-382 (2002).
47. Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, Willoughby DA. Inducible cyclooxygenase may have anti-inflammatory properties. Nature Med. 5(6), 698-701 (1999).
48. Ando M, Murakami Y, Kojima F et al. Retrovirally introduced prostaglandin D2 synthase suppresses lung injury induced by bleomycin. Am. J. Respir. Cell Mol. Biol. 28(5), 582-591 (2003).
49. Murakami Y, Akahoshi T, Hayashi I et al. Inhibition of monosodium urate monohydrate crystal-induced acute inflammation by retrovirally transfected prostaglandin D synthase. Arthritis Rheum. 48(10), 2931-2941 (2003).
50. Watanabe K, Fujii Y, Nakayama K et al. Cloning, nucleotide sequence and gene expression of bovine lung prostaglandin F synthetase. Adv. Prostaglandin Thromboxane Leukot. Res. 19, 462-465 (1989).
51. Suzuki T, Fujii Y, Miyano M, Chen LY, Takahashi T, Watanabe K. cDNA cloning, expression, and mutagenesis study of liver-type prostaglandin F synthase. J. Biol. Chem. 274(1), 241-248 (1999).
52. Nakashima K, Ueno N, Kamei D et al. Coupling between cyclooxygenases and prostaglandin F(2α) synthase. Detection of an inducible, glutathione-activated, membrane-bound prostaglandin F(2α)-synthetic activity. Biochim. Biophys. Acta. 1633(2), 96-105 (2003).
53. Zhang L, Chase MB, Shen RF. Molecular cloning and expression of murine thromboxane synthase. Biochem. Biophys. Res. Commun. 194(2), 741-748 (1993).
54. Miyata A, Hara S, Yokoyama C, Inoue H, Ullrich V, Tanabe T. Molecular cloning and expression of human prostacyclin synthase. Biochem. Biophys. Res. Commun. 200(3), 1728-1734 (1994).
55. Oates JA, Fitzgerald GA, Branch RA, Jackson EK, Knapp HR, Roberts LJ 2nd. Clinical implications of prostaglandin and thromboxane A2 formation (2). N. Engl. J. Med. 319(12), 761-767 (1988).
56. Castellani S, Paniccia R, Di Serio C et al. Thromboxane inhibition improves renal perfusion and excretory function in severe congestive heart failure. J. Am. Coll. Cardiol. 42(1), 133-139 (2003).
57. Stichtenoth DO, Thoren S, Bian H, Peters-Golden M, Jakobsson PJ, Crofford LJ. Microsomal prostaglandin E synthase is regulated by pro-inflammatory cytokines and glucocorticoids in primary rheumatoid synovial cells. J. Immunol. 167(1), 469-474 (2001).
58. Kojima F, Naraba H, Sasaki Y, Okamoto R, Koshino T, Kawai S. Coexpression of microsomal prostaglandin E synthase with cyclooxygenase-2 in human rheumatoid synovial cells. J. Rheumatol. 29(9), 1836-1842 (2002).
59. Westman M, Korotkova M, af Klint E et al. Expression of microsomal prostaglandin E synthase 1 in rheumatoid arthritis synovium. Arthritis Rheum. 50(6), 1774-1780 (2004).
60. Kojima F, Naraba H, Miyamoto S, Beppu M, Aoki H, Kawai S. Membrane-associated prostaglandin E synthase-1 is upregulated by pro-inflammatory cytokines in chondrocytes from patients with osteoarthritis. Arthritis Res. Ther. 6(4), R355-R365 (2004).
61. Claveau D, Sirinyan M, Guay J et al. Microsomal prostaglandin E synthase-1 is a major terminal synthase that is selectively upregulated during cyclooxygenase-2-dependent prostaglandin E2 production in the rat adjuvant-induced arthritis model. J. Immunol. 170(9), 4738-4744 (2003).
62. Guay J, Bateman K, Gordon R, Mancini J, Riendeau D. Carrageenan-induced paw edema in rat elicits a predominant prostaglandin E2 (PGE2) response in the central nervous system associated with the induction of microsomal PGE2 synthase-1. J. Biol. Chem. 279(23), 24866-24872 (2004).
63. Trebino CE, Stock JL, Gibbons CP et al. Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc. Natl Acad. Sci. USA 100(15), 9044-9049 (2003).
64. Uematsu S, Matsumoto M, Takeda K, Akira S. Lipopolysaccharide-dependent prostaglandin E(2) production is regulated by the glutathione-dependent prostaglandin E(2) synthase gene induced by the Toll-like receptor 4/ MyD88/NF-IL6 pathway. J. Immunol. 168(11), 5811-5816 (2002).
65. Trebino CE, Eskra JD, Wachtmann TS, Perez JR, Carty TJ, Audoly LP. Redirection of eicosanoid metabolism in mPGES-1-deficient macrophages. J. Biol. Chem. 280(17), 16579-16585 (2005).
66. Kamei D, Yamakawa K, Takegoshi Y et al. Reduced pain hypersensitivity and inflammation in mice lacking microsomal prostaglandin e synthase-1. J. Biol. Chem. 279(32), 33684-33695 (2004).
67. Mabuchi T, Kojima H, Abe T et al. Membrane-associated prostaglandin E synthase-1 is required for neuropathic pain. Neuroreport. 15(9), 1395-1398 (2004).
68. Engblom D, Saha S, Engstrom L et al. Microsomal prostaglandin E synthase-1 is the central switch during immune-induced pyresis. Nature Neurosci. 6(11), 1137-1138 (2003).
69. Saha S, Engstrom L, Mackerlova L, Jakobsson PJ, Blomqvist A. Impaired febrile responses to immune challenge in mice deficient in microsomal prostaglandin E synthase-1. Am. J. Physiol. Regul. Integr. Comp. Physiol. 288(5), R1100-R1107 (2005).
70. Wooley PH, Luthra HS, Stuart JM, David CS. Type II collagen-induced arthritis in mice. I. Major histocompatibility complex (I region) linkage and antibody correlates. J. Exp. Med. 154(3), 688-700 (1981).
71. Williams KI, Higgs GA. Eicosanoids and inflammation. J. Pathol. 156(2), 101-110 (1988).
72. Peters-Golden M, Brock TG. 5-lipoxygenase and FLAP. Prostaglandins Leukot. Essent. Fatty Acids 69(2-3), 99-109 (2003).
73. Samuelsson B. The discovery of the leukotrienes. Am. J. Respir. Crit. Care Med. 161(2 Pt. 2), S2-S6 (2000).
74. Bonnet C, Bertin P, Cook-Moreau J, Chable-Rabinovitch H, Treves R, Rigaud M. Lipoxygenase products and expression of 5-lipoxygenase and 5-lipoxygenase-activating protein in human cultured synovial cells. Prostaglandins 50(3), 127-135 (1995).
75. Liagre B, Vergne P, Rigaud M, Beneytout JL. Arachidonate 15-lipoxygenase of reticulocyte-type in human rheumatoid arthritis type B synoviocytes and modulation of its activity by pro-inflammatory cytokines. J. Rheumatol. 26(5), 1044-1051 (1999).
76. Harada S, Sugiyama E, Takebe S et al. Co-operative induction of 15-lipoxygenase in rheumatoid synovial cells by IL-4 and pro-inflammatory cytokines. Clin. Exp. Rheumatol. 21(6), 753-758 (2003).
77. Liagre B, Vergne P, Rigaud M, Beneytout JL. Expression of arachidonate platelet-type 12-lipoxygenase in human rheumatoid arthritis type B synoviocytes. FEBS Lett. 414(1), 159-164 (1997).
78. Marcouiller P, Pelletier JP, Guevremont M et al. Leukotriene and prostaglandin synthesis pathways in osteoarthritic synovial membranes: regulating factors for interleukin-1β synthesis. J. Rheumatol. 32(4), 704-712 (2005).
79. Vane JR. Adventures and excursions in bioassay: the stepping stones to prostacyclin. In: Les Prix Nobel: Nobel Prizes, Presentations, Biographies and Lectures. Almqvist & Wiksell, Stockholm, Sweden, 181-206 (1982).
80. Clària J, Serhan CN. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc. Natl Acad. Sci. USA 92, 9475-9479 (1995).
81. Serhan CN, Chiang N. Lipid-derived mediators in endogenous anti-inflammation and resolution: lipoxins and aspirin-triggered 15-epi-lipoxins. Scientific World Journal 2, 169-204 (2002).
82. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol. Rev. 79(4), 1193-1226 (1999).
83. Abe H, Takeshita T, Nagata K et al. Molecular cloning, chromosome mapping and characterization of the mouse CRTH2 gene, a putative member of the leukocyte chemoattractant receptor family. Gene 227(1), 71-77 (1999).
84. Regan JW. EP2 and EP4 prostanoid receptor signaling. Life Sci. 74(2-3), 143-153 (2003).
85. Hatae N, Sugimoto Y, Ichikawa A. Prostaglandin receptors: advances in the study of EP3 receptor signaling. J. Biochem. (Tokyo) 131(6), 781-784 (2002).
86. McCoy JM, Wicks JR, Audoly LP. The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis. J. Clin. Invest. 110(5), 651-658 (2002).
87. Akaogi J, Yamada H, Kuroda Y, Nacionales DC, Reeves WH, Satoh M. Prostaglandin E2 receptors EP2 and EP4 are upregulated in peritoneal macrophages and joints of pristane-treated mice and modulate TNF-α and IL-6 production. J. Leukoc. Biol. 76(1), 227-236 (2004).
88. Giles H, Leff P. The biology and pharmacology of PGD2. Prostaglandins 35(2), 277-300 (1988).
89. Tanaka K, Ogawa K, Sugamura K, Nakamura M, Takano S, Nagata K. Cutting edge: differential production of prostaglandin D2 by human helper T cell subsets. J. Immunol. 164(5), 2277-2280 (2000).
90. Tetlow LC, Woolley DE. Mast cells, cytokines, and metalloproteinases at the rheumatoid lesion: dual immunolocalisation studies. Ann. Rheum. Dis. 54(11), 896-903 (1995).
91. Woolley DE. The mast cell in inflammatory arthritis. N. Engl. J. Med. 348(17), 1709-1711 (2003).
92. Matsuoka T, Hirata M, Tanaka H et al. Prostaglandin D2 as a mediator of allergic asthma. Science 287(5460), 2013-2017 (2000).
93. Spik I, Brenuchon C, Angeli V et al. Activation of the prostaglandin D2 receptor DP2/CRTH2 increases allergic inflammation in mouse. J. Immunol. 174(6), 3703-3708 (2005).
94. Barnes NC, Piper PJ, Costello JF. Comparative effects of inhaled leukotriene C4, leukotriene D4, and histamine in normal human subjects. Thorax 39, 500-504 (1984)
95. Busse W, Kraft M. Cysteinyl leukotrienes in allergic inflammation: strategic target for therapy. Chest 127(4), 1312-1326 (2005).
96. Yokomizo T, Izumi T, Chang K, Takuwa Y, Shimizu T. A G protein coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 387, 620-624 (1997).
97. Yokomizo T, Kato K, Terawaki K, Izumi T, Shimizu T. A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J. Exp. Med. 192, 421-432 (2000).
98. Stankova J, Turcotte S, Harris M, Rola-Pleszczynski M. Modulation of the leukotriene B4 receptor-1 expression by dexamethasone: potential mechanism for enhanced neutrophil survival. J. Immunol. 168, 3570-3576 (2002).
99. Huang WW, Garcia-Zepeda EA, Sauty A, Oettgen HC, Rothenberg ME, Luster AD. Molecular and biological characterization of the murine leukotriene B4 receptor expressed on eosinophils. J. Exp. Med. 188, 1063-1074 (1998).
100. Obinata H, Yokomizo T, Shimizu T, Izumi T. Glucocorticoids upregulate leukotriene B4 receptor-1 expression during neutrophilic differentiation of HL-60 cells. Biochem. Biophys. Res. Commun. 309, 114-119 (2003).
101. Fiore S, Romano M, Reardon EM, Serhan CN. Induction of functional lipoxin A4 receptors in HL-60 cells. Blood 81, 3395-3403 (1993).
102. Fiore S, Maddox JF, Perez HD, Serhan CN. Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor. J. Exp. Med. 180, 253-260 (1994).
103. Sodin-Semrl S, Taddeo B, Tseng D, Varga J, Fiore S. Lipoxin A4 inhibits IL-1 β-induced IL-6, IL-8, and matrix metalloproteinase-3 production in human synovial fibroblasts and enhances synthesis of tissue inhibitors of metalloproteinases. J. Immunol. 164(5), 2660-2666 (2000).
104. Gavins FN, Yona S, Kamal AM, Flower RJ, Perretti M. Leukocyte anti-adhesive actions of annexin 1: ALXR- and FPR-related anti-inflammatory mechanisms. Blood 101, 4140-4147 (2003).
105. Devchand PR, Arita M, Hong S et al. Human ALX receptor regulates neutrophil recruitment in transgenic mice: roles in inflammation and host defense. FASEB J. 17(6), 652-659 (2003).
106. Egg D, Gunther R, Herold M, Kerschbaumer F. Prostaglandins E2 and F2 alpha concentrations in the synovial fluid in rheumatoid and traumatic knee joint diseases. Z. Rheumatol. 39(5-6), 170-175 (1980).
107. Portanova JP, Zhang Y, Anderson GD et al. Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin-6 production in vivo. J. Exp. Med. 184(3), 883-891 (1996).
108. Kojima F, Naraba H, Sasaki Y, Beppu M, Aoki H, Kawai S. Prostaglandin E2 is an enhancer of interleukin-1β-induced expression of membrane-associated prostaglandin E synthase in rheumatoid synovial fibroblasts. Arthritis Rheum. 48(10), 2819-2828 (2003).
109. Inoue H, Takamori M, Shimoyama Y, Ishibashi H, Yamamoto S, Koshihara Y. Regulation by PGE2 of the production of interleukin-6, macrophage colony stimulating factor, and vascular endothelial growth factor in human synovial fibroblasts. Br. J. Pharmacol. 136(2), 287-295 (2002).
110. Masuko-Hongo K, Sato T, Nishioka K. Chemokines differentially induce matrix metalloproteinase-3 and prostaglandin E2 in human articular chondrocytes. Clin. Exp. Rheumatol. 23(1), 57-62 (2005).
111. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ 2nd. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc. Natl Acad. Sci. USA 87, 9383-9387 (1990).
112. Helmersson J, Basu S. F(2)-isoprostane and prostaglandin F(2 α) metabolite excretion rate and day to day variation in healthy humans. Prostaglandins Leukot. Essent. Fatty Acids 65, 99-102 (2001).
113. Basu S, Whiteman M, Mattey DL, Halliwell B. Raised levels of F(2)-isoprostanes and prostaglandin F(2α) in different rheumatic diseases. Ann. Rheum. Dis. 60, 627-631 (2001).
114. Gopaul NK, Anggard EE, Mallet AI, Betteridge DJ, Wolff SP, Nourooz-Zadeh J. Plasma 8-epi-PGF2 α levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Lett. 368, 225-229 (1995).
115. Basu S, Eriksson M. Oxidative injury and survival during endotoxemia. FEBS Lett. 438, 159-160 (1998).
116. Willoughby DA. Effects of prostaglandins PGF2α and PGE1 on vascular permeability. J. Pathol. Bacteriol. 96, 381-387 (1968).
117. Herlin T, Fogh K, Christiansen NO, Kragballe K. 15-HETE inhibits leukotriene B4 formation and synovial cell proliferation in experimental arthritis. Agents Actions. 29, 52-53 (1990).
118. Griffiths RJ, Pettipher ER, Koch K et al. Leukotriene B4 plays a critical role in progression, of collagen-induced arthritis. Proc. Natl Acad. Sci. USA 92, 517-521 (1995).
119. Sawazaki Y. Leukotriene B4, leukotriene C4 and prostaglandin E2 in the serum, synovial fluid and synovium in patients with rheumatoid arthritis. Nippon Ika Daigaku Zasshi. 56(6), 559-564 (1989).
120. Moilanen E, Alanko J, Nissila M, Hamalainen M, Isomaki H, Vapaatalo H. Eicosanoid production in rheumatoid synovitis. Agents Actions. 28(3-4), 290-297 (1989).
121. Canetti CA, Leung BP, Culshaw S, McInnes IB, Cunha FQ, Liew FY. IL-18 enhances collagen-induced arthritis by recruiting neutrophils via TNF-α and leukotriene B4. J. Immunol. 171(2), 1009-1015 (2003).
122. Marcus SL, Miyata KS, Zhang B, Subramani S, Rachubinski RA, Capone JP. Diverse peroxisome proliferator-activated receptors bind to the peroxisome proliferator-responsive elements of the rat hydratase/ dehydrogenase and fatty acyl-CoA oxidase genes but differentially induce expression. Proc. Natl Acad. Sci. USA 90(12), 5723-5727 (1993).
123. Kapoor M, Shaw O, Appleton I. Possible anti-inflammatory role of COX-2-derived prostaglandins: implications for inflammation research. Curr. Opin. Investig. Drugs. 6(5), 461-466 (2005).
124. Ji JD, Cheon H, Jun JB. Effects of peroxisome proliferator-activated receptor-gamma (PPAR-γ) on the expression of inflammatory cytokines and apoptosis induction in rheumatoid synovial fibroblasts and monocytes. J. Autoimmun. 17(3), 215-221 (2001).
125. Fahmi H, Di Battista JA, Pelletier JP, Mineau F, Ranger P, Martel-Pelletier J. Peroxisome proliferator-activated receptor γ activators inhibit interleukin1-β-induced nitric oxide and matrix metalloproteinase 13 production in human chondrocytes. Arthritis Rheum. 44(3), 595-607 (2001).
126. Fahmi H, Pelletier JP, Di Battista JA, Cheung HS, Fernandes JC, Martel-Pelletier J. Peroxisome proliferator-activated receptor γ activators inhibit MMP-1 production in human synovial fibroblasts likely by reducing the binding of the activator protein 1. Osteoarthritis Cartilage. 10(2), 100-108 (2002).
127. Tsubouchi Y, Kawahito Y, Kohno M, Inoue K, Hla T, Sano H. Feedback control of the arachidonate cascade in rheumatoid synoviocytes by 15-deoxy-δ(12,14)-prostaglandin J2. Biochem. Biophys. Res. Commun. 283(4), 750-755 (2001).
128. Farrajota K, Cheng S, Martel-Pelletier J et al. Inhibition of interleukin-1beta-induced cyclooxygenase-2 expression in human synovial fibroblasts by 15-deoxy-δ12, 14-prostaglandin J2 through a histone deacetylase-independent mechanism. Arthritis Rheum. 52(1), 94-104 (2005).
129. Fahmi H, Pelletier JP, Mineau F, Martel-Pelletier J. 15d-PGJ(2) is acting as a 'dual agent' on the regulation of COX-2 expression in human osteoarthritic chondrocytes. Osteoarthritis Cartilage. 10(11), 845-848 (2002).
130. Cheng S, Afif H, Martel-Pelletier J et al. Activation of peroxisome proliferator-activated receptor γ inhibits interleukin-1β-induced membrane-associated prostaglandin E2 synthase-1 expression in human synovial fibroblasts by interfering with Egr-1. J. Biol. Chem. 279(21), 22057-22065 (2004).
131. Quraishi O, Mancini JA, Riendeau D. Inhibition of inducible prostaglandin E(2) synthase by 15-deoxy-δ(12, 14)-prostaglandin J(2) and polyunsaturated fatty acids. Biochem. Pharmacol. 63(6), 1183-1189 (2002).
132. Gilroy DW, Colville-Nash PR, McMaster S, Sawatzky DA, Willoughby DA, Lawrence T. Inducible cyclooxygenase-derived 15-deoxy(δ) 12-14PGJ2 brings about acute inflammatory resolution in rat pleurisy by inducing neutrophil and macrophage apoptosis. FASEB J. 17(15), 2269-2271 (2003).
133. Ianaro A, Ialenti A, Maffia P, Pisano B, Di Rosa M. Role of cyclopentenone prostaglandins in rat carrageenin pleurisy. FEBS Lett. 508(1), 61-66 (2001).
134. Kawahito Y, Kondo M, Tsubouchi Y et al. 15-deoxy-δ(12, 14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J. Clin. Invest. 106(2), 189-197 (2000).
135. Shan ZZ, Masuko-Hongo K, Dai SM, Nakamura H, Kato T, Nishioka K. A potential role of 15-deoxy-δ(12, 14)-prostaglandin J2 for induction of human articular chondrocyte apoptosis in arthritis. J. Biol. Chem. 279(36), 37939-37950 (2004).
136. Bell-Parikh LC, Ide T, Lawson JA, McNamara P, Reilly M, FitzGerald GA. Biosynthesis of 15-deoxy-δ 12, 14-PGJ2 and the ligation of PPARγ. J. Clin. Invest. 112(6), 945-955 (2003).
137. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN. Lipid mediator class switching during acute inflammation: signals in resolution. Nature Immunol. 2, 612-619 (2001).
138. Wu SH, Lu C, Dong L, Zhou GP, He ZG, Chen ZQ. High dose of lipoxin A4 induces apoptosis in rat renal interstitial fibroblasts. Prostaglandins Leukot. Essent. Fatty Acids 73(2), 127-137 (2005).
139. Goh J, Baird AW, O'Keane C et al. Lipoxin A(4) and aspirin-triggered 15-epi-lipoxin A(4) antagonize TNF-α-stimulated neutrophil-enterocyte interactions in vitro and attenuate TNF-α-induced chemokine release and colonocyte apoptosis in human intestinal mucosa ex vivo. J. Immunol. 167(5), 2772-2780 (2001).
140. Serhan CN, Jain A, Marleau S et al. Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. J. Immunol. 171(12), 6856-6865 (2003).
141. Papayanni A, Serhan CN, Phillips ML, Rennke HG, Brady HR. Transcellular biosynthesis of lipoxin A4 during adhesion of platelets and neutrophils in experimental immune complex glomerulonephritis. Kidney Int. 47, 1295 (1994).
142. Chiang N, Gronert K, Clish CB, O'Brien JA, Freeman MW, Serhan CN. Leukotriene B4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion. J. Clin. Invest. 104(3), 309-316 (1999).
143. Jozsef L, Zouki C, Petasis NA, Serhan CN, Filep JG. Lipoxin A4 and aspirin-triggered 15-epi-Lipoxin A4 inhibit peroxynitrite formation, NF-κB and AP-1 activation, and IL-8 gene expression in human leukocytes. Proc. Natl Acad. Sci. USA 99(20), 13266-13271 (2002).
144. Paul-Clark MJ, Van Cao T, Moradi-Bidhendi N, Cooper D, Gilroy DW. 15-epi-Lipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation. J. Exp. Med. 200(1), 69-78 (2004).
145. Sodin-Semrl S, Spagnolo A, Mikus R, Barbaro B, Varga J, Fiore S. Opposing regulation of interleukin-8 and NF-κB responses by lipoxin A4 and serum amyloid A via the common lipoxin A receptor. Int. J. Immunopathol. Pharmacol. 17(2), 145-156 (2004).
146. Sodin-Semrl S, Spagnolo A, Barbaro B, Varga J, Fiore S. Lipoxin A4 counteracts synergistic activation of human fibroblast-like synoviocytes. Int. J. Immunopathol. Pharmacol. 17(1), 15-25 (2004).
147. Thomas E, Leroux JL, Blotman F, Chavis C. Conversion of endogenous arachidonic acid to 5, 15-diHETE and lipoxins by polymorphonuclear cells from patients with rheumatoid arthritis. Inflamm. Res. 44(3), 121-124 (1995).
148. Serhan CN, Hong S, Gronert K et al. Resolvins: a family of bioactive products of mega-3 fatty acid transformation circuits initiated by aspirin treatment that counter pro-inflammation signals. J. Exp. Med. 196, 1025-1037 (2002).
149. Arita M, Clish CB, Serhan CN. The contributions of aspirin and microbial oxygenase to the biosynthesis of anti-inflammatory resolvins: novel oxygenase products from omeda-3 polyunsaturated fatty acids. Biochem. Biophys. Res. Commun. 338, 149-157 (2005).
150. Vanderhoek JY, Bryant RW, Bailey JM. Inhibition of leukotriene biosynthesis by the leukocyte product 15-hydroxy-5,8,11,13-eicosatetraenoic acid. J. Biol. Chem. 255, 10664 (1980).
151. Ternowitz T, Fogh K, Kragballe K. 15-Hydroxyeicosatetraenoic acid (15-HETE) specifically inhibits LTB4-induced chemotaxis of human neutrophils. Skin Pharmacol. 1, 93-99 (1988).
152. Fogh K, Hansen ES, Herlin T. 15-Hydroxy-eicosatetraenoic acid (15-HETE) inhibits carrageenan-induced experimental arthritis and reduces synovial fluid leukotriene B4 (LTB4). Prostaglandins 37, 213-228 (1989).
153. Fogh K, Sogaard H, Herlin T, Kragballe K. Improvement of psoriasis vulgaris after intralesional injections of 15-hydroxyeicosatetraenoic acid (15-HETE). J. Am. Acad. Dermatol. 18, 279-285 (1988).
154. Huang JT, Welch JS, Ricote M et al. Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase. Nature 400(6742), 378-382 (1999).
155. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 268, 6610-6614 (1993).
156. Gupta S, Crofford LJ. An update on specific COX-2 inhibitors. The COXIBs. Bull. Rheum. Dis. 50(1), 1-4 (2001).
157. Laine L, Harper S, Simon T et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase-2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology 117, 776-783 (1999).
158. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. 343(21), 1520-1528 (2000).
159. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284, 1247-1255 (2000).
160. Kivitz AJ, Nayiager S, Schimansky T, Gimona A, Thurston HJ, Hawkey C. Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis. Aliment Pharmacol. Ther. 19, 1189-1198 (2004).
161. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascuolar events and rofecoxib. cumulative meta-analysis. Lancet 364, 2021-2029 (2004).
162. Bresalier RS, Sandler RS, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 352, 1092-1102 (2005).
163. White WB, Faich G, Borer JS, Makuch RW. Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. Am. J. Cardiol. 92, 411-418 (2003).
164. Solomon SD, McMurray JJV, Pfeffer MA et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. 352, 1071-1080 (2005).
165. Yamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S, Kawai S. Nonsteroidal anti-inflammatory drugs induce apoptosis in association with activation of peroxisome proliferator-activated receptor γ in rheumatoid synovial cells. J. Pharmacol. Exp. Ther. 302(1), 18-25 (2002).
166. Yamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S, Kawai S. Aspirin and sodium salicylate inhibit proliferation and induce apoptosis in rheumatoid synovial cells. J. Pharm. Pharmacol. 54(12), 1675-1679 (2002).
167. Kusunoki N, Yamazaki R, Kawai S. Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase-2 inhibitors. Arthritis Rheum. 46(12), 3159-3167 (2002).
168. Kusunoki N, Ito T, Sakurai N, Suguro T, Handa H, Kawai S. A novel celecoxib derivative potently induces apoptosis of human synovial fibroblasts. J. Pharmacol. Exp. Ther. 314(2), 796-803 (2005).